Focus on Protein Kinases for
Drug Development

ProQinase GmbH is a contract research organization (CRO) which provides a Protein Kinase Technology Platform for preclinical drug development of protein kinase inhibitors in oncology and other therapeutic areas. Currently 185 in-house produced recombinant protein kinases are offered for sale and 320 kinases are available for in vitro kinase assay services (HTS, selectivity profiling and IC₅₀ determination). Hits derived from in vitro kinase assays can be characterized at ProQinase in cellular phosphorylation assays and in a cellular angiogenesis assay. 

For further evaluation of lead compounds ProQinase offers various in vivo assays including subcutaneous xenograft and orthotopic tumor models, and an unique angiogenesis assay. ProQinase´s drug  development service portfolio is completed by a clinical biomarker assay service for determination of different biomarker proteins in serum or plasma samples derived from clinical trials.